Trial Profile

An observational study of REN001

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavodelpar (Primary)
Indications Glycogen storage disease type V; Inborn error metabolic disorders; Mitochondrial myopathies
Focus Adverse reactions
Acronyms FORWARD

Most Recent Events

31 Jan 2023 Status has been changed to completed, according to a Reneo Pharmaceuticals media release.
29 Aug 2022 According to a Reneo Pharmaceuticals media release, results from the study were presented in a poster at the International Network for Fatty Acid Oxidation Research and Management (INFORM) annual meeting, being held in Freiburg, Germany August 28-29, 2022.
14 Sep 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com